CJC-1295 (no DAC), Ipamorelin, GHRP-2 (Blend)

🧬 INTRODUCTION: The Tripartite Secretagogue Synergy

Within the specialized field of neuroendocrine research, the strategic modulation of growth hormone (GH) pulsatility represents a sophisticated model for investigating somatic development, metabolic partitioning, and cellular regeneration. The evolution from dual-pathway to triple-pathway secretagogue combinations marks a significant advancement in experimental endocrinology .

The CJC-1295 (no DAC), Ipamorelin, and GHRP-2 Blend embodies this methodological apex. This formulation unites a stabilized GHRH analog with two mechanistically distinct GHRPs, creating a comprehensive research tool for interrogating the somatotropic axis under controlled laboratory conditions .

CJC-1295 without DAC (also designated MOD GRF 1-29) functions as a DPP-4-resistant GHRH analog, stimulating endogenous GH synthesis and release in a physiologically relevant pulsatile pattern . Ipamorelin, a pentapeptide GHSR agonist, provides highly selective GH release with minimal effect on other pituitary hormones . GHRP-2 (Pralmorelin) , a hexapeptide ghrelin mimetic, delivers potent GH pulse amplification with distinct orexigenic properties .

At Buy Peptides Online USA, we supply this triple-action blend as a high-purity, GMP-manufactured research reagent. Each constituent undergoes independent High Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) verification prior to precision blending—the only scientifically defensible quality standard for heterogeneous peptide formulations.

✅ WHAT IS THE CJC-1295 (NO DAC) + IPAMORELIN + GHRP-2 BLEND?

This blend unites three mechanistically distinct but functionally synergistic peptide classes into a single, pre-formulated research tool:

🔹 Component Breakdown & Mechanistic Rationale

🔬 CJC-1295 without DAC (MOD GRF 1-29)
CJC-1295 is a synthetic 30-amino acid peptide and analog of growth hormone-releasing hormone (GHRH) . The “no DAC” (Drug Affinity Complex) variant is chemically identical to MOD GRF 1-29, a tetrasubstituted analog of sermorelin (GRF 1-29) . Strategic amino acid substitutions—specifically Tyr¹→D-Ala², Asp³→Ala¹⁵, and Gly¹⁵→Ala¹⁵—confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation, extending bioactive half-life to approximately 30 minutes (compared to native GRF’s 7-minute half-life) .

Critical Distinction: Unlike the DAC-conjugated variant which binds albumin for extended release (half-life ~6-8 days), the no DAC version produces rapid, physiologically relevant GH pulses that closely mimic endogenous male secretory patterns . This makes it the preferred GHRH analog for modeling pulsatile GH dynamics and circadian rhythm studies .

Sequence (Single Letter): Y-D-A-I-F-T-Q-S-Y-R-K-V-L-A-Q-L-S-A-R-K-L-L-Q-D-I-L-S-R-NH₂
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: ~3367.95 g/mol

🔬 Ipamorelin
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed by Novo Nordisk. It functions as a highly selective agonist of the growth hormone secretagogue receptor (GHSR-1a) .

Key Mechanistic Attributes:

• Selectivity: Exhibits minimal stimulatory effect on ACTH, prolactin, FSH, LH, TSH, or cortisol—distinguishing it from GHRP-2 and GHRP-6 .
• Potency: Demonstrates GH-releasing efficacy comparable to GHRP-6 with significantly fewer off-target endocrine effects .
• Appetite Profile: Produces mild to negligible orexigenic effects, making it suitable for metabolic studies where appetite is a confounding variable .
• Stability: Resistant to enzymatic degradation due to D-amino acid incorporation and C-terminal amidation .

Sequence (Single Letter): Aib-H-d-2-Nal-d-F-K-NH₂
Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: ~711.9 g/mol

🔬 GHRP-2 (Pralmorelin; KP-102)
GHRP-2 is a synthetic hexapeptide (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂) developed by Kaken Pharmaceutical. It functions as a potent, full agonist of the GHSR-1a .

Key Mechanistic Attributes:

• Pulse Amplification: Demonstrates superior GH pulse amplitude compared to other GHRPs, with rapid onset of action .
• Somatostatin Antagonism: Reduces hypothalamic somatostatin tone, removing tonic inhibition on pituitary somatotrophs.
• Orexigenic Effect: Significantly stimulates appetite via NPY/AgRP neuron activation—a distinguishing feature from Ipamorelin .
• Cortisol/PRL Elevation: May transiently increase ACTH, cortisol, and prolactin at higher doses .

The Tripartite Synergy:
CJC-1295 (no DAC) primes the pituitary for GH synthesis and establishes pulsatile release. Ipamorelin provides selective, sustained GH amplification with minimal endocrine confounds. GHRP-2 delivers potent pulse amplitude and somatostatin antagonism. Together, they enable researchers to model the complete GHRH–ghrelinergic regulatory axis with precision .

🧪 PRODUCT SPECIFICATIONS & TECHNICAL DATA SHEET

Critical Quality Note: Due to significant physicochemical differences between CJC-1295 (30aa, ~3.4 kDa), Ipamorelin (5aa, ~0.7 kDa), and GHRP-2 (6aa, ~0.8 kDa), simultaneous HPLC purity quantitation is analytically impossible in a blended format. Co-injection produces peak overlap, retention time shifting, and molar response bias. Therefore, we employ component-wise pre-analytical verification—the gold standard for heterogeneous peptide blends .

📊 Comprehensive Peptide Specifications Table

🔬 VERIFIED QUALITY: THE TRIPLE SECRETAGOGUE VALIDATION PROTOCOL

Analytical Challenge: CJC-1295 (30-mer, hydrophobic), Ipamorelin (5-mer, moderately hydrophilic), and GHRP-2 (6-mer, aromatic-rich) possess divergent chromatographic behaviors. Co-injection produces overlapping peaks and inaccurate purity assignments .

Our 4-Tier Verification Protocol:

✅ Tier 1: Component Pre-Analysis. Each raw peptide is individually analyzed via reverse-phase HPLC (C18 column, optimized gradient elution per component) to confirm ≥98% purity. Identity confirmed via ESI-MS or MALDI-TOF MS against reference standards .

✅ Tier 2: Precision Blending. Components are gravimetrically dispensed in ISO 7 (Class 10,000) cleanroom environments using calibrated micro-balances (±0.01 mg accuracy). Blend ratios verified by dual weighing.

✅ Tier 3: Post-Blend Identity Confirmation. The final blend undergoes MS to confirm the presence and correct monoisotopic mass signatures of all three peptides (3368 Da, 712 Da, 818 Da).

✅ Tier 4: Endotoxin & Bioburden. LAL chromogenic assay verification of <0.05 EU/mg—essential for cell culture applications .

“In triple-peptide blends, component-wise pre-validation with full analytical traceability is the only scientifically defensible quality standard. Simultaneous HPLC claims are analytically invalid.” — Adapted from pharmacopeial guidelines for complex peptide formulations .

🧬 PRIMARY RESEARCH APPLICATIONS & MECHANISM OF ACTION

This blend is designed exclusively for controlled laboratory investigations. Below are the predominant domains of preclinical inquiry:

1. 📈 Somatotropic Axis & GH Pulsatility Research

Key Focus: Neuroendocrine feedback loops, pulse amplitude vs. frequency modulation, circadian rhythm entrainment.

• CJC-1295 (no DAC) models the GHRH-mediated component of GH synthesis and pulsatile release .
• Ipamorelin provides selective, sustained GHSR activation without confounding ACTH/prolactin elevation .
• GHRP-2 delivers high-amplitude pulse potentiation and somatostatin antagonism .
• Research Model: Primary rat pituitary cell culture; serial blood sampling in porcine or murine models; GH-ELISA; cAMP response element (CRE) reporter assays .

2. 🧠 Metabolic Partitioning & Body Composition

Key Focus: Lipolysis, nitrogen retention, insulin sensitivity, adipocyte differentiation.

• GH/IGF-1 axis activation promotes protein synthesis and lipid mobilization.
• Ipamorelin demonstrates minimal effect on glucose homeostasis compared to other GHRPs .
• GHRP-2 enables controlled studies of ghrelinergic appetite signaling without exogenous ghrelin administration .
• Research Model: Diet-induced obesity (DIO) rodent models; metabolic cage studies; DEXA body composition analysis; 3T3-L1 adipocyte differentiation assays.

3. 🦴 Skeletal Health & Bone Mineral Density

Key Focus: Osteoblast proliferation, fracture healing, osteoporosis models.

• IGF-1 mediation stimulates osteoblast differentiation and collagen matrix deposition.
• Ipamorelin + GHRP-2 combination has demonstrated increased bone mineral content in rat models .
• Research Model: Ovariectomized (OVX) osteoporosis models; micro-CT analysis; osteoblast alkaline phosphatase assays.

4. 🔬 GHRH–GHSR Pathway Interaction Mapping

Key Focus: GPCR crosstalk, receptor desensitization, biased agonism.

• Enables comparative analysis of two distinct GHSR agonists (Ipamorelin vs. GHRP-2) in combination with a GHRH analog .
• Research Model: HEK293 cells transfected with GHSR-1a; β-arrestin recruitment assays; intracellular calcium flux.

❄️ HANDLING, STORAGE & RECONSTITUTION PROTOCOL

Peptides are environmentally labile polymers. Improper handling introduces experimental confounders and invalidates data .

🧊 Storage Integrity Protocol

Critical Note on Ipamorelin Stability: Ipamorelin exhibits rapid degradation above 4°C post-reconstitution. Storage at -20°C post-reconstitution is contraindicated (freeze damage). Prepare fresh aliquots if experiments exceed 14 days .

💧 Standardized Reconstitution Protocol (6mg Total Mass)

Based on published laboratory protocols for 2mg CJC + 2mg Ipamorelin + 2mg GHRP-2 :

1. Equilibration: Allow vial to reach room temperature in a desiccated environment (15-20 min) to prevent moisture condensation on the hygroscopic lyophilized cake.
2. Solvent: Inject 3.0 mL of Bacteriostatic Water (0.9% Benzyl Alcohol).
   • Final Concentration: 2.0 mg/mL total peptide.
   • Component Concentrations: 0.67 mg/mL each (CJC-1295, Ipamorelin, GHRP-2).
3. Technique: Direct fluid against the vial wall. Do NOT shake (introduces oxygen, denatures tertiary structure). Gently swirl or roll for 30-60 seconds.
4. Visual Inspection: Solution should be clear and colorless. Discard if particulate matter, haziness, or discoloration present.

📊 Syringe Measurement Reference (U-100 Insulin Syringe)

At 3.0 mL reconstitution volume (0.67 mg/mL concentration per peptide) :

Note: For precise low-dose measurements, prepare a serial dilution or reconstitute with larger volume (e.g., 4.0 mL BAC water yields 0.5 mg/mL per component; 50 mcg = 0.1 mL = 10 units).

❓ FREQUENTLY ASKED QUESTIONS (FAQ)

Q: Why include BOTH Ipamorelin AND GHRP-2? Isn’t one GHRP sufficient?

A: This blend is designed for comparative and synergistic research. Ipamorelin provides selective GH release with minimal endocrine confounds (cortisol, prolactin, appetite). GHRP-2 provides maximal pulse amplitude and orexigenic signaling. Together, they enable researchers to:

1. Model the complete ghrelinergic signaling spectrum.
2. Compare receptor activation profiles within a single experimental system.
3. Investigate GHSR desensitization and biased agonism .

Q: What is the definitive difference between CJC-1295 ‘with DAC’ and ‘without DAC’?

A: CJC-1295 with DAC contains a Drug Affinity Complex that covalently binds to albumin, resulting in a half-life of ~6-8 days and sustained, non-pulsatile GH release (female-like pattern). CJC-1295 without DAC (MOD GRF 1-29) has a half-life of ~30 minutes, producing rapid, pulsatile GH spikes that mimic endogenous male physiology. For research modeling physiological GH pulsatility, no DAC is the appropriate choice .

Q: What is the typical research dosing frequency for this triple blend?

A: Due to the short half-life of CJC-1295 no DAC (~30 min) and GHRP-2 (~45 min), this blend models acute pulsatile administration. Typical research protocols involve 2-3x daily administration in chronic studies (e.g., 0800, 1400, 2000) to mimic the natural ultradian rhythm. A minimum 3-hour interval between administrations is recommended to prevent receptor desensitization .

Q: Does this blend cause significant prolactin or cortisol elevation in animal models?

A: Ipamorelin is specifically selected for minimal effect on ACTH, prolactin, and cortisol . GHRP-2 may cause transient, dose-dependent elevations in these hormones. The net effect in blend format is attenuated compared to GHRP-2 alone but may still be detectable. This is an experimental variable to be measured, not a defect .

Q: Do you provide medical dosage instructions?

A: Absolutely not. As a Research Use Only (RUO) supplier, we strictly prohibit providing medical or veterinary instructions. Determining the appropriate dose, concentration, and administration route for your specific IACUC-approved protocol is the sole responsibility of the qualified Principal Investigator (PI) .

🧬 PEPTIDE STRUCTURE & STABILITY INSIGHTS

Why “no DAC”?
The Drug Affinity Complex (DAC) is a reactive succinimidyl group that covalently binds to lysine residues on albumin. CJC-1295 without DAC lacks this modification entirely. It is simply a tetrasubstituted GRF 1-29 analog with four strategic amino acid substitutions for DPP-4 resistance. It is not a “truncated” or “inferior” version—it is a mechanistically distinct research tool for pulsatile GH modeling .

Aib in Ipamorelin:
Ipamorelin contains α-aminoisobutyric acid (Aib) , a non-proteinogenic amino acid that induces helical conformation and confers exceptional proteolytic stability. This contributes to its longer half-life and selective receptor activation profile .

D-Amino Acids in GHRP-2:
GHRP-2 contains D-Ala and D-Phe. The incorporation of D-amino acids provides resistance to exopeptidase degradation, significantly extending bioactive half-life compared to all-L amino acid peptides.

C-Terminal Amidation (-NH₂):
All three peptides feature C-terminal amidation. This neutralizes the negative charge of the terminal carboxyl group, improving receptor recognition and proteolytic stability .

🚀 WHY PURCHASE CJC-1295 (NO DAC) + IPAMORELIN + GHRP-2 BLEND FROM BUY PEPTIDES ONLINE USA?

The peptide supply landscape is heterogeneous. We differentiate through methodological transparency and researcher-first logistics.

✅ Component-Verified Purity: Each of the three constituents is tested individually (≥98% HPLC/MS) prior to precision blending—essential for heterogeneous blends where simultaneous HPLC is invalid .
✅ Third-Party Transparency: Independent COA documentation per batch—no proprietary secrecy. Full analytical traceability.
✅ GMP-Ancillary Manufacturing: Produced in ISO 9001-aligned facilities; rigorous environmental monitoring and documentation .
✅ Cold-Chain Packaging: Lyophilized peptides shipped with temperature-indicating desiccants and insulated containers.
✅ Authenticity Guarantee: Full replacement or refund if product fails independent verification of stated specifications.
✅ Secure Crypto Payments: Bitcoin, Ethereum, USDT accepted for discreet, frictionless transactions.
✅ 24/7 Technical Support: Protocol consultation regarding reconstitution, solubility, and handling (RUO context only).
✅ USA-Based Operations: Rapid fulfillment from domestic distribution hubs. Free shipping on orders over $300.
✅ Bulk Availability: Volume discounts for institutional laboratories (contact for custom quotas).

📦 PACKAGING & DELIVERY INTELLIGENCE

• Primary Container: Sterile, crimp-sealed Type I borosilicate glass vial.
• Protection: Foil pouch with integrated desiccant; anti-static cushioning.
• Discretion: Plain, non-descript outer carton.
• Lead Time: Orders processed within 1-2 business days. USA delivery: 2-5 business days.
• International: Worldwide shipping available, subject to local import/export compliance.

⚖️ LEGAL & COMPLIANCE DISCLAIMER

STRICT RESEARCH USE ONLY (RUO).

• NOT FOR HUMAN OR VETERINARY CONSUMPTION.
• NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.
• NOT FDA APPROVED.

This product is intended solely for in vitro or animal model research by qualified professionals in a controlled laboratory setting. All product information, including proposed mechanisms and applications, is derived from peer-reviewed literature and is presented for educational purposes only. It does not constitute medical advice or a claim regarding the treatment or cure of any disease or condition .

By purchasing, the buyer confirms compliance with all applicable institutional, local, state, and federal regulations.

⭐ RESEARCHER INSIGHTS

Synthesized feedback from our institutional and private research clientele:

🔹 “The batch-specific COA included pre-blend HPLC traces for all three components. Exactly what we need for the methods section of our manuscript.” — Ph.D., Neuroendocrinology
🔹 “I appreciate the inclusion of both Ipamorelin and GHRP-2 in one blend. Allows us to compare receptor activation profiles without ordering three separate vials.” — Lead Scientist, Metabolic Research
🔹 “Consistent solubility. Reconstitutes clear with no residue. Vial integrity was perfect despite cross-country shipping.” — Verified Buyer
🔹 “Accurate labeling—’no DAC’ confirmed via MS. Many suppliers conflate MOD GRF with DAC version. Thank you for the precision.” — Principal Investigator, Animal Science
🔹 “Crypto checkout was seamless. Shipping to the East Coast took 3 days. Will reorder for our next study cohort.” — Verified Buyer

💼 SERVICE ECOSYSTEM

• 24/7 Support: Live chat and email response for urgent research inquiries.
• Product Replacement: Transparent, no-hassle policy for compromised vials.
• Authenticity Guarantee: Backed by verifiable, shareable analytical data.
• Technical Consultation: Educational guidance on standard peptide handling and reconstitution.
• Complaint Handling: Direct escalation pathway to Quality Assurance.

🚀 Advance from dual-pathway to tripartite secretory modeling. Add the CJC-1295 (no DAC) + Ipamorelin + GHRP-2 Blend to your laboratory requisition cart now.